

Category	N=249	Percentage
Age at diagnosis (years)		
- < 40	8	3
- 40 - 59	101	41
- 60 - 75	128	51
- > 75	12	5
Sex		
- Female	247	99
- Male	2	1
Menopausal status^a		
- Postmenopausal	183	73
- Premenopausal	65	26
- Unknown	1	1
Previous breast cancer event		
- Yes	29	12
- No	220	88
Tumor size		
- T1a (0.1 – 0.5 cm)	1	0
- T1b (0.6 – 1 cm)	29	12
- T1c (1.1-2 cm)	134	54
- T2 (2.1 – 5 cm)	74	30
- T3 (> 5cm)	11	4
Histotype		
- Ductal infiltrating	202	81
- Lobular infiltrating	43	17
- Papillary	2	1
- Other	2	1
Positive axillary lymph nodes		
- 0	178	72
- Micrometastasis	13	5
- 1 node	43	17
- 2 nodes	8	3
- 3 nodes	2	1
- Unknown	5	2
Hormone receptor status		
- Estrogen receptor positive	249	100
- Progesterone receptor positive	206	83
Histopathological grade at diagnosis		
- Grade 1	33	13
- Grade 2	194	78
- Grade 3	22	9
Lymphovascular invasion		
- Absent	187	75
- Present	62	25
Surgery		
- Partial mastectomy	187	75
- Mastectomy	62	25
Adjuvant radiotherapy		
- Yes	214	86
- No	27	11
- Unkown	8	3

Adjuvant hormonotherapy		
- AI	146	59
- TAM	52	21
- TAM then AI	11	4
- AI then TAM	8	3
- LHRHa + AI	3	1
- Refused by patient	4	2
- Unkown	25	10
Adjuvant chemotherapy		
- No chemotherapy	135	54
- Taxane and anthracycline	52	21
- Taxane and cyclophosphamide	54	22
- Other protocol	2	1
- Unkown	6	2
EPclin risk		
- Low-risk	98	39
- High-risk	151	61
Estimated adjuvant chemotherapy benefit at 10-year overall survival according to PREDICT (%)		
- < 2	85	34
- [2-5]	156	63
- > 5	8	3

TAM: Tamoxifen

AI : Aromatase inhibitor

LHRHa : Luteinizing hormone-releasing hormone agonists

EPclin : EndoPredict Clinic risk score

^aMenopausal status is at the time of diagnosis, and all males are considered postmenopausal

Table 1: Baseline characteristics